CA3039927C - Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2 - Google Patents

Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2 Download PDF

Info

Publication number
CA3039927C
CA3039927C CA3039927A CA3039927A CA3039927C CA 3039927 C CA3039927 C CA 3039927C CA 3039927 A CA3039927 A CA 3039927A CA 3039927 A CA3039927 A CA 3039927A CA 3039927 C CA3039927 C CA 3039927C
Authority
CA
Canada
Prior art keywords
masp
antibody
inhibitory
fibrosis
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3039927A
Other languages
English (en)
Other versions
CA3039927A1 (fr
Inventor
Nigel John Brunskill
Gregory A. Demopulos
Tom DUDLER
Hans-Wilhelm Schwaeble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leicester
Omeros Corp
Original Assignee
University of Leicester
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by University of Leicester, Omeros Medical Systems Inc filed Critical University of Leicester
Priority to CA3210384A priority Critical patent/CA3210384A1/fr
Publication of CA3039927A1 publication Critical patent/CA3039927A1/fr
Application granted granted Critical
Publication of CA3039927C publication Critical patent/CA3039927C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Dans un aspect, l'invention concerne des méthodes de réduction de la protéinurie chez un sujet humain souffrant ou présentant un risque de développer une néphropathie aux immunoglobulines A (IgAN). Les méthodes comprennent l'étape d'administration, à un sujet qui en a besoin, d'une quantité d'un agent inhibiteur de MASP-2 efficace pour inhiber l'activation du complément dépendant de MASP-2.
CA3039927A 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2 Active CA3039927C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3210384A CA3210384A1 (fr) 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US62/407,979 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/399,524 2017-01-05
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 2017-03-27
US201762527926P 2017-06-30 2017-06-30
US62/527,926 2017-06-30
PCT/US2017/056386 WO2018071701A1 (fr) 2016-10-13 2017-10-12 Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3210384A Division CA3210384A1 (fr) 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2

Publications (2)

Publication Number Publication Date
CA3039927A1 CA3039927A1 (fr) 2018-04-19
CA3039927C true CA3039927C (fr) 2023-10-10

Family

ID=61906454

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3210384A Pending CA3210384A1 (fr) 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2
CA3039927A Active CA3039927C (fr) 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3210384A Pending CA3210384A1 (fr) 2016-10-13 2017-10-12 Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2

Country Status (19)

Country Link
EP (1) EP3525798A4 (fr)
JP (1) JP6893554B2 (fr)
KR (1) KR102348939B1 (fr)
CN (2) CN110177557A (fr)
AU (1) AU2017342428B2 (fr)
BR (1) BR112019007426A2 (fr)
CA (2) CA3210384A1 (fr)
CL (2) CL2019000909A1 (fr)
GE (2) GEP20267856B (fr)
IL (1) IL265981B2 (fr)
JO (1) JOP20190068B1 (fr)
MA (1) MA46541A (fr)
MX (1) MX2019004074A (fr)
MY (1) MY205849A (fr)
PH (1) PH12019500711B1 (fr)
SG (1) SG11201902941UA (fr)
UA (1) UA126908C2 (fr)
WO (1) WO2018071701A1 (fr)
ZA (1) ZA201902933B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
US20230265215A1 (en) 2021-12-10 2023-08-24 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
CN116392488B (zh) * 2023-05-22 2025-03-28 中南大学湘雅医院 一种生物碱化合物在制备防治糖尿病肾病的药物中的应用
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法
WO2026026712A1 (fr) * 2024-07-31 2026-02-05 前沿生物药业(南京)股份有限公司 Arnsi pour inhiber l'expression du gene masp2 et son modificateur et son utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE024996T2 (en) * 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en) * 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
DK2488203T3 (en) * 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9102721B2 (en) * 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
BR112013025917A2 (pt) * 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
NZ629682A (en) * 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
JP2016539919A (ja) * 2013-10-17 2016-12-22 オメロス コーポレーション Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
KR102528260B1 (ko) * 2016-01-05 2023-05-04 유니버시티 오브 레스터 필요로 하는 대상체에서 섬유증의 억제 방법
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق

Also Published As

Publication number Publication date
JP2019534271A (ja) 2019-11-28
KR102348939B1 (ko) 2022-01-12
JOP20190068B1 (ar) 2024-12-22
WO2018071701A1 (fr) 2018-04-19
MX2019004074A (es) 2019-06-10
NZ753260A (en) 2021-11-26
CN116726163A (zh) 2023-09-12
KR20190063475A (ko) 2019-06-07
CN110177557A (zh) 2019-08-27
EP3525798A1 (fr) 2019-08-21
IL265981A (en) 2019-06-30
AU2017342428A1 (en) 2019-05-23
MA46541A (fr) 2019-08-21
BR112019007426A2 (pt) 2019-07-02
MY205849A (en) 2024-11-15
CA3039927A1 (fr) 2018-04-19
IL265981B1 (en) 2025-01-01
PH12019500711A1 (en) 2019-11-18
GEP20247587B (en) 2024-01-25
SG11201902941UA (en) 2019-05-30
CA3210384A1 (fr) 2018-04-19
UA126908C2 (uk) 2023-02-22
CL2019000909A1 (es) 2019-06-14
CL2019003485A1 (es) 2020-04-13
EP3525798A4 (fr) 2020-07-08
JP6893554B2 (ja) 2021-06-23
PH12019500711B1 (en) 2024-04-17
IL265981B2 (en) 2025-05-01
GEP20267856B (en) 2026-02-10
ZA201902933B (en) 2023-05-31
AU2017342428B2 (en) 2021-02-04
JOP20190068A1 (ar) 2019-04-01

Similar Documents

Publication Publication Date Title
US20240424091A1 (en) Methods for Inhibiting Fibrosis in a Subject in Need Thereof
US20250092157A1 (en) Methods for inhibiting fibrosis in a subject in need thereof
US20210079116A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
CA3039927C (fr) Traitement de la nephropathie lupique dependante aux steroides au moyen d'une composition qui inhibe l'activation d'un complement dependant a masp-2
HK40099516A (zh) 用於减少患有免疫球蛋白a肾病的人受试者中的蛋白尿的方法
OA18820A (en) Methods for inhibiting fibrosis in a subject in need thereof.
OA19229A (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy.
HK40013366A (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
EA043102B1 (ru) Способ уменьшения протеинурии у человека, страдающего от иммуноглобулин а нефропатии
BR112018013723B1 (pt) Uso de um anticorpo monoclonal inibitório de masp-2
BR122023002007B1 (pt) Uso de um anticorpo monoclonal inibidor de masp-2 ou fragmento de ligação ao antígeno do mesmo
EA049795B1 (ru) Способ подавления фиброза у нуждающегося в этом субъекта
EA049345B1 (ru) Способ подавления фиброза у нуждающегося в этом субъекта

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190409